| pubmed-article:19114462 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19114462 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:19114462 | lifeskim:mentions | umls-concept:C0020792 | lld:lifeskim |
| pubmed-article:19114462 | lifeskim:mentions | umls-concept:C1304890 | lld:lifeskim |
| pubmed-article:19114462 | lifeskim:mentions | umls-concept:C0025519 | lld:lifeskim |
| pubmed-article:19114462 | lifeskim:mentions | umls-concept:C1514468 | lld:lifeskim |
| pubmed-article:19114462 | lifeskim:mentions | umls-concept:C1572601 | lld:lifeskim |
| pubmed-article:19114462 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:19114462 | pubmed:dateCreated | 2009-2-19 | lld:pubmed |
| pubmed-article:19114462 | pubmed:abstractText | An in vivo study in rats showed a cranberry juice product to inhibit the intestinal first-pass metabolism of the CYP3A substrate nifedipine. However, a clinical study involving the CYP3A probe substrate midazolam and a different cranberry juice product showed no interaction. Because the composition of bioactive components in natural products can vary substantially, a systematic in vitro-in vivo approach was taken to identify a cranberry juice capable of inhibiting enteric CYP3A in humans. First, the effects of five cranberry juices, coded A through E, were evaluated on midazolam 1'-hydroxylation activity in human intestinal microsomes. Juice E was the most potent, ablating activity at 0.5% juice (v/v) relative to control. Second, juice E was fractionated to generate hexane-, chloroform-, butanol-, and aqueous-soluble fractions. The hexane- and chloroform-soluble fractions at 50 microg/ml were the most potent, inhibiting by 77 and 63%, respectively, suggesting that the CYP3A inhibitors reside largely in these more lipophilic fractions. Finally, juice E was evaluated on the oral pharmacokinetics of midazolam in 16 healthy volunteers. Relative to water, juice E significantly increased the geometric mean area under the curve (AUC)(0-infinity) of midazolam by approximately 30% (p=0.001), decreased the geometric mean 1'-hydroxymidazolam/midazolam AUC(0-infinity) ratio by approximately 40% (p<0.001), and had no effect on geometric mean terminal half-life, indicating inhibition of enteric, but not hepatic, CYP3A-mediated first-pass metabolism of midazolam. This approach both showed a potential drug interaction liability with cranberry juice and substantiated that rigorous in vitro characterization of dietary substances is required before initiation of clinical drug-diet interaction studies. | lld:pubmed |
| pubmed-article:19114462 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19114462 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19114462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19114462 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19114462 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:19114462 | pubmed:issn | 1521-009X | lld:pubmed |
| pubmed-article:19114462 | pubmed:author | pubmed-author:OberliesNicho... | lld:pubmed |
| pubmed-article:19114462 | pubmed:author | pubmed-author:PaineMary FMF | lld:pubmed |
| pubmed-article:19114462 | pubmed:author | pubmed-author:KashubaAngela... | lld:pubmed |
| pubmed-article:19114462 | pubmed:author | pubmed-author:DeesE... | lld:pubmed |
| pubmed-article:19114462 | pubmed:author | pubmed-author:GrafTyler NTN | lld:pubmed |
| pubmed-article:19114462 | pubmed:author | pubmed-author:NgoNgocN | lld:pubmed |
| pubmed-article:19114462 | pubmed:author | pubmed-author:YanZhixiaZ | lld:pubmed |
| pubmed-article:19114462 | pubmed:author | pubmed-author:CarrizosaDani... | lld:pubmed |
| pubmed-article:19114462 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19114462 | pubmed:volume | 37 | lld:pubmed |
| pubmed-article:19114462 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19114462 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19114462 | pubmed:pagination | 514-22 | lld:pubmed |
| pubmed-article:19114462 | pubmed:dateRevised | 2011-9-26 | lld:pubmed |
| pubmed-article:19114462 | pubmed:meshHeading | pubmed-meshheading:19114462... | lld:pubmed |
| pubmed-article:19114462 | pubmed:meshHeading | pubmed-meshheading:19114462... | lld:pubmed |
| pubmed-article:19114462 | pubmed:meshHeading | pubmed-meshheading:19114462... | lld:pubmed |
| pubmed-article:19114462 | pubmed:meshHeading | pubmed-meshheading:19114462... | lld:pubmed |
| pubmed-article:19114462 | pubmed:meshHeading | pubmed-meshheading:19114462... | lld:pubmed |
| pubmed-article:19114462 | pubmed:meshHeading | pubmed-meshheading:19114462... | lld:pubmed |
| pubmed-article:19114462 | pubmed:meshHeading | pubmed-meshheading:19114462... | lld:pubmed |
| pubmed-article:19114462 | pubmed:meshHeading | pubmed-meshheading:19114462... | lld:pubmed |
| pubmed-article:19114462 | pubmed:meshHeading | pubmed-meshheading:19114462... | lld:pubmed |
| pubmed-article:19114462 | pubmed:meshHeading | pubmed-meshheading:19114462... | lld:pubmed |
| pubmed-article:19114462 | pubmed:meshHeading | pubmed-meshheading:19114462... | lld:pubmed |
| pubmed-article:19114462 | pubmed:meshHeading | pubmed-meshheading:19114462... | lld:pubmed |
| pubmed-article:19114462 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19114462 | pubmed:articleTitle | Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. | lld:pubmed |
| pubmed-article:19114462 | pubmed:affiliation | Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7360, USA. | lld:pubmed |
| pubmed-article:19114462 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19114462 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19114462 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
